Form 4: Aligos Therapeutics Director, Margarita Chavez, Acquires Stock Options

Director Margarita Chavez acquired stock options for 120,000 shares of Aligos Therapeutics at an exercise price of $0.55 on August 7, 2024.

Summary

• Margarita Chavez, a director of Aligos Therapeutics, Inc. (ALGS), filed a Form 4 on August 9, 2024.
• The filing reports a transaction that occurred on August 7, 2024, where Chavez acquired stock options for 120,000 shares.
• The exercise price of the stock options is $0.55.
• The options vest in 36 equal monthly installments starting August 7, 2024, and will be fully vested on the third anniversary of that date.
• Chavez directly owns 120,000 derivative securities following the reported transaction.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director. While insider confidence is generally positive, this is a standard part of compensation.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates changes in the beneficial ownership of Aligos Therapeutics' securities by a director.

Comparison to Industry Standards

• Stock option grants to directors are a common form of compensation in the biotechnology industry.
• The vesting schedule of 36 months is also typical for such grants.
• Comparing the size of the grant to those of directors at comparable companies like Arrowhead Pharmaceuticals or Dicerna Pharmaceuticals would provide further context.

Stakeholder Impact

• The grant of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates